U.S. judge invalidates Acorda multiple sclerosis drug patents

U.S. judge invalidates Acorda multiple sclerosis drug patents


A federal judge in Delaware on Friday struck down key patents held by Acorda Therapeutics Inc related to its multiple sclerosis drug Ampyra, and the stock fell 24 percent before being halted. The ruling by U.S. District Judge Leonard Stark opens the door for generic versions of the drug by makers including Mylan Inc and Roxane Laboratories Inc. Those companies had sought regulatory approval to sell a generic version of Ampyra, but Acorda sued them, seeking a declaration that its patents on the drugs were valid.



from Biotech News